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Purpose: To determine the long-term outcome after endovascular aneurysm repair (EVAR) of infrarenal abdominal aortic
aneurysms (AAA).
Methods: Review the primary outcome measures of patients treated with endovascular grafts (EG) in the Lifeline
Registry of EVAR. The registry contains data on 2,664 EG patients and 334 open surgical control (SC) patients
collected under four multicenter Investigational Device Exemption (IDE) clinical trials that lead to United States
Food and Drug Administration (FDA) approval with mandatory 5-year follow-up. Primary outcome measures
include operative mortality, AAA-related death, all-cause mortality, aneurysm rupture, and surgical conversion.
Results: Pooled data from IDE clinical trials revealed that EG patients were 3 years older (73  8 years) than SC
patients (70  8 years, P < .01) and had significantly more cardiac comorbidities before treatment. However, there
was no difference in 30-day operative mortality between EG (1.7%) and SC (1.4%) (P  .72). Both EG and SC were
successful in preventing rupture, with freedom from aneurysm rupture in 99.8% of EG and 100% of SC patients at
1 year (P  .51). Freedom from rupture remained at 99% in years 1 to 6 after EG, with no increasing risk of late
rupture. There was no significant difference in the AAA-related death rate at 1 year between EG (98.2%) and SC
(98.6%) (P  .64). Freedom from AAA-related death remained at 98% in years 1 to 6 after EG, with no increasing
risk of late AAA-related death. Kaplan-Meier analysis at 6 years revealed freedom from aneurysm rupture in 99%,
freedom from AAA-related death in 98%, and freedom from surgical conversion in 95% of EG patients. There was
no difference in survival at 4 years between EG (74%) and SC (71%) (P  .49). Overall EG patient survival at 5 years
was 66% and at 6 years was 52%. Women had a higher risk of rupture (2.4%) than men (1.2%) (P  .01) and a higher
rate of surgical conversion (8.3%) than men (3.8%) (P < .01) but had the same low AAA-related death rate (3.5%)
as men (2.1%) (P  .16) at 5 years. Most secondary interventional procedures (85%) were performed <30 days after
EVAR. Freedom from secondary intervention was 84% at 1 year and 78% at 5 years.
Conclusions: Endovascular aneurysm repair using FDA-approved devices is a safe, effective, and durable treatment for
anatomically suited patients with infrarenal abdominal aortic aneurysms. ( J Vasc Surg 2005;42:1-10.)The Lifeline Registry of Endovascular Aneurysm Re-
pair (EVAR) was established in 1998 to evaluate the long-
term outcome of endovascular treatment of patients with
infrarenal abdominal aortic aneurysms (AAA). A standard-
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doi:10.1016/j.jvs.2005.05.012ized reporting format was developed to allow pooling of
data from patients treated with endovascular grafts from
different manufacturers to determine the overall effective-
ness of EVAR.1,2
Since 1999, the United States Food and Drug Ad-
ministration (FDA) has approved five endovascular grafts
for clinical use in the United States: the Guidant AnCure
(Indianapolis, Ind), Medtronic AneuRx (Santa Rosa,
Calif), Gore Excluder (Flagstaff, Ariz), Endologix Pow-
erLink (Irvine, Calif) and Cook Zenith (Bloomington,
Ind). Each device was approved on the basis of a multi-
center, controlled Investigational Device Exemption
(IDE) clinical trial comparing the endograft (EG) to
open surgical repair (surgical controls, SC). Each IDE
clinical trial was sponsored by the manufacturer of the
device, and the protocol, inclusion and exclusion criteria,
and clinical results have been individually pub
lished.3-7
A condition of FDA approval for each of these de-
vices was clinical and imaging follow up of all EG patients
for a 5-year period after completion of the clinical trial.
The manufacturers of four of the FDA-approved devices
1
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their IDE clinical trial data on EG and SC patients along
with long-term follow up data to the Lifeline Registry.
This report is focused on the primary outcome measures
of endovascular aortic aneurysm repair, namely operative
mortality, aneurysm-related death, all-cause mortality,
aneurysm rupture, and surgical conversion.
METHODS
All clinical data from the four IDE clinical trials submit-
ted by the manufacturers are included in the registry. Data
was received as Statistical Analysis System (SAS) datasets
(SAS Institute Inc, Cary, NC) or Excel (Microsoft, Belling-
ham, Wash) spreadsheets and converted to the common
registry data format by matching variable names from the
manufacturer case report forms to the registry case report
forms. Discrepancies between definitions of endpoints are
footnoted, when appropriate; for example, AAA enlarge-
ment is defined as a 5-mm increase from predischarge,
while onemanufacturer compares it to 30 days. Pooled data
from patients treated with endovascular grafts under con-
trolled IDE clinical trials (EG-IDE) were compared with
pooled data from surgical control (SC) patients from these
same clinical trials.
Complete 1-year follow-up was required for both EG
and SC groups in accord with the IDE protocols. Complete
5-year follow-up of EG-IDE patients, including aneurysm
imaging, was required of manufacturers as a condition of
FDA approval. Long-term follow up requirements1 year
for SC patients was limited to survival status.
Table I. Investigational Device Exemption clinical trials
patient numbers
Device Endografts Surgical controls
AnCure 1040 111
AneuRx 1204 66
Excluder 235 99
PowerLink 185 58
Total 2664 334
Table II. Demographics and comorbidities of Investigatio
Endograft patien
N  2664
Age (yrs) 73.1  7.8 (45-9
Age (% 65 yrs) 13.1 (270/2063)
Gender (% male) 88.6 (1828/2063
Race (% white) 94.5 (1948/2062
CAD or MI (%) 82.7 (1705/2063
CHF (%) 10.5 (217/2063)
Hypertension (%) 64.0 (1321/2063
COPD (%) 29.2 (602/2063)
Diabetes mellitus (%) 12.4 (255/2063)
Renal failure (%)* 3.4 (70/2063)
Pre-op aneurysm size (mm) 55.8  10.2 (21-1
CAD, Coronary artery disease; MI, myocardial infarction; CHF, congestive
*Renal failure is defined as a serum creatinine level 3.0 mg/dLThe primary outcome measures of aneurysm repair
were:
(a) operative mortality, defined as death during the initial
hospitalization or death from any cause 30 days of
the primary procedure;
(b) aneurysm-related death, defined as death from any
cause 30 days of the primary procedure, death 30
days of a secondary procedure or surgical conversion,
or any death due to aneurysm rupture or graft compli-
cation;
(c) all-cause mortality (survival);
(d) aneurysm rupture; and
(e) conversion to open surgical aneurysm repair.
Secondary outcome measures for EG such as endoleak,
aneurysm sac enlargement, endograft migration, and graft
patency are not considered in this analysis; however, the
overall secondary interventional procedure rate is reported.
Statistical analysis. Baseline characteristics of the EG
and SC groups were compared by using the two-tailed t test
for continuous variables and the 2 or Fisher’s exact test, as
necessary, for discrete/categoric data. Descriptive statistics
are listed as mean  standard deviation for continuous
variables and percent (frequency) for categoric variables.
Kaplan-Meier estimates, using the log-rank test, were used
to compare the primary outcome between groups for free-
dom from death (ie, survival), aneurysm-related death,
rupture, and conversion to open repair. Differences were
considered significant if P  .05. The Cox proportional
hazard multivariate logistic regression was performed to
assess predicate factors of outcome (ie, potential indepen-
dent risk factors). All statistical analyses were performed by
New England Research Institutes, Inc, (NERI) in Water-
town, Mass.
RESULTS
Patient population. The numbers of patients from
each of the IDE clinical trial included in the Lifeline Reg-
istry are shown in Table I. The registry contains 2,664
evice Exemption clinical trial patients
Surgical controls P
N  334
70.0  7.8 (46-87) .0001
23.7 (79/334) .0001
79.3 (265/334) .0001
96.6 (259/268) .1350
59.3 (198/334) .0001
6.0 (20/334) .0101
67.1 (224/334) .2827
28.7 (96/334) .8701
12.6 (42/334) .9122
3.0 (10/334) .7493
57.1  11.7 (31-100) .1240
failure; COPD, chronic obstructive pulmonary disease.nal D
ts
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)
)
)
)
20)
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(SC) patients.
Baseline demographic information and comorbid fac-
tors are shown in Table II. There were statistically signifi-
cant differences between the EG-IDE group and the SC
group before aneurysm treatment. Endovascular patients
were an average of 3 years older (73 vs 70 years, P  .01)
and had significantly more coronary artery disease (83% vs
59% in SC, P .01) and congestive heart failure (11% vs 6%
in SC, P  .01) than surgical controls. Surgical control
patients were more likely to be 65 years old (24% vs 13%
in EG, P .01) and more likely to be women (21% vs 13%
in EG, P  .01).
There was no difference in preoperative aneurysm
size between EG and SC, with mean a aneurysm diame-
ter of 5.6  1.0 cm in EG patients and 5.7  1.2 cm in
Fig 1. Kaplan-Meier (K-M) analysis of aneurysm-relat
(EG-IDE) group versus surgical controls (SC).SC patients. Mean follow-up time was 2.8  1.6 years(maximum, 6.7 years) for the EG-IDE group and 1.9 
1.4 years (maximum, 4.3 years) for the SC group.
Primary outcome measures. Kaplan-Meier analyses
of the primary endpoints for EG-IDE patients extended to
6 years and are shown on Figs 1 to 4.
Operative mortality. The 30-day operative mortality
was 1.7% for the EG-IDE group and 1.4% for the SC
group. There was no significant difference in operative
mortality rate between EG-IDE and SC patients (P .72).
Operative mortality in the EG-IDE group for men was
1.5% compared with 2.1% for women (P .42). Operative
mortality in the SC group for men was 1.1% compared with
1.5% for women (P  .48).
AAA-related death. Most AAA-related deaths
(80%) occurred during the initial 30-day perioperative
period (30-day operative mortality noted previously).
ortality of endograft-Investigational Device Exemptioned mThree AAA-related deaths occurred in the interval 30
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group. There was no significant difference in AAA-re-
lated death rate at 1 year between EG-IDE (1.8%) and
SC (1.4%) (P  .63, Kaplan-Meier log rank test). Eight
AAA-related deaths occurred in the EG patients from
years 1 to 6. Freedom from AAA-related death after EG
by Kaplan-Meier analysis remained unchanged at 98%
from years 1 to 6, with no increasing risk of late AAA-
related death (Fig 1). The only significant predictor of
AAA-related mortality was a larger preoperative aneu-
rysm size, as seen in Table III, A .
All-cause mortality (survival). There was no signifi-
cant difference in survival between EG-IDE and SC pa-
tients (Fig 2). Survival data extended to 6 years in EG-IDE
patients but was limited beyond 4 years in the SC group
(the longest SC follow-up time was 4.3 years). The Kaplan-
Meier survival comparison between groups was, therefore,
performed at 4 years. There was no difference in survival at
4 years between SC (71%) and EG-IDE (74%) (P  .49).
Survival for EG-IDE at 5 years and 6 years was 66% and
52%. Significant predictors of all cause-mortality included
increased age and the presence of comorbid factors, includ-
ing coronary artery disease/myocardial infarction, conges-
tive heart failure, chronic obstructive pulmonary disease,
and renal failure, as listed in Table III, B. Larger preoper-
ative aneurysm size was also a significant predictor of mor-
tality.
Rupture. No aneurysm ruptures were reported
among SC patients, and 18 ruptures occurred among EG
patients. These included three early (30 days) and 15 late
ruptures (30 days). Ruptures were reported from three of
the four IDE clinical trials in the registry. There was no
difference in freedom from aneurysm rupture between
EG-IDE patients (99.8%) and SC patients (100%) at 1 year
by Kaplan-Meier analysis (log-rank test, P  .51) (Fig 3).
The late aneurysm rupture rate was not available for SC
patients.
The freedom-from-rupture rate for EG patients re-
mained at 99% from years 1 to 6, with no suggestion of an
Table IIIA. Cox proportional hazard for aneurysm-
related mortality in the endograft-Investigation Device
Exemption patients
Variable
Hazard
ratio
95% Hazard ratio
confidence limits P
Age 1.041 0.998 1.086 .0606
Female 1.650 0.713 3.817 .2420
CAD/MI 2.432 0.577 10.247 .2257
CHF 2.148 0.989 4.665 .0534
Hypertension 0.927 0.478 1.797 .8218
COPD 1.257 0.646 2.445 .5005
DM 0.981 0.380 2.533 .9683
Renal failure 1.775 0.524 6.013 .3569
Aneurysm size 1.034 1.009 1.060 .0080
CAD, Coronary artery disease; MI, myocardial infarction; CHF, congestive
heart failure; COPD, chronic obstructive pulmonary disease.increasing late risk of rupture after EG. Significant predic-tors of increased risk of aneurysm rupture were female
gender and preoperative aneurysm size, as listed in Table
III, C. Women had a threefold increase in risk of rupture
compared with men (hazard ratio, 3.4; P  .03).
Surgical conversion. Open surgical repair after pri-
mary aneurysm treatment was reported from each of the
IDE clinical trials in the registry and was confined to the
endograft patient group. Among the EG-IDE patients, 96
patients have required conversion to open repair. Of these,
68 (71%) were early (30 days of the primary procedure),
andmany occurred during the early experience with EVAR.
There have been 28 late surgical conversions (30 days to 6
years). The 30-day operative mortality rate for early surgical
conversion was 5 (7.4%) of 68 and for late surgical conver-
sion was 0 (0%) of 28. Freedom from surgical conversion
was 97% at years 1 through 3, 96% at year 4, and 95% at
years 5 and 6 (Fig 4).
Predictors of the need for surgical conversion were
female gender, coronary artery disease/myocardial infarc-
tion and larger preoperative aneurysm size, as seen in Table
III, D. Women had a threefold higher likelihood of need-
ing surgical conversion than men (hazard ratio, 3.7;
P  .01).
Secondary interventions. Secondary interventional
procedures after the primary index procedure were re-
ported in the endograft patient group. Among the EG-IDE
patients, 487 patients have required a secondary interven-
tion. Of these, 415 (85%) were early (30 days of the
primary endograft procedure). There have been 76 late
surgical conversions (30 days to 6 years). Freedom from
secondary intervention was 84% at 1 year, 83% at 2 years,
82% at 3 years, 81% at 4 years, 78% at 5 years, and 73% at
6-years (Fig 5).
Gender analysis—endovascular group. A primary
outcome analysis by gender of the EG-IDE showed a
significant difference in age between women and men, with
women being 3.6 years older (76.4  7.7 years; range, 28
to 96 years) than men (72.8  7.8 years; range, 45 to 96
years) (P  .01). However, there was no significant differ-
ence in all-cause mortality or AAA-related mortality be-
tween women and men by Kaplan-Meier analysis. Opera-
tive mortality (30 day) for women (2.2%) compared with
men (1.5%) was not significantly different (P  .42). Cu-
mulative AAA-related death at 5 years was not significantly
different for women (3.3%) than for men (2.1%) (P  .25,
log-rank test). Survival at 5 years was no different in women
(60%) than in men (67%) (P .31). Women had a twofold
greater risk of aneurysm rupture (2.5%) thanmen (1.2%) (P
 .01). Women were also more likely to require surgical
conversion (8.5%) than men (3.9%) (P  .01); however,
this difference was entirely due to a higher risk of early
(30 day) conversion among women (17 of 19 conver-
sions occurred during the perioperative period). There was
no difference in late surgical conversion rate between
women and men.
Aneurysm size analysis. Preoperative aneurysm size
was reported in 2,019 EG patients. Of these, 1,040 were
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rysms (5.5 cm). Preoperative aneurysm size was a
significant predictive factor for all primary end points
(all-cause mortality, aneurysm-related mortality, rup-
ture, and surgical conversion) as summarized in Table
III, A to D . During the 5-year follow-up period, patients
with large aneurysms had a threefold higher risk of
rupture (2.4%) than patients with small aneurysms
(0.7%) (P  .01). However, there was no difference in
the 5-year AAA-related death rate (3.0% in large AAA
and 2.0% in small AAA) (P  .21, log-rank test) or the
5-year surgical conversion rate (5.3% in large AAA and
4.2% in small AAA) (P  .20, log-rank test) between
patients with large and small aneurysms. Patients with
large aneurysms had a reduced survival at 5 years (64%)
compared with patients with small aneurysms (69%) (P
Fig 2. Kaplan-Meier (K-M) analysis of all-cause mortal
group versus surgical controls (SC)..01).DISCUSSION
The Society for Vascular Surgery established the Life-
line Registry to monitor the long-term safety and effective-
ness of EVAR using FDA-approved devices. To this end, an
effort was made to include data from each of the controlled
IDE clinical trials, which are the basis for FDA device
approval. Since the FDA mandated 5-year monitored, clin-
ical, and imaging follow-up of each IDE patient cohort as a
condition of approval, this provided a unique opportunity
for the most comprehensive long-term perspective of
EVAR.
The registry, working in cooperation with industry and
NERI, established a mechanism for data management,
uniform reporting, and pooling of long-term outcomes
from the various clinical trials. Themanufacturers agreed to
share their data with the registry, granting oversight of the
endograft-Investigational Device Exemption (EG-IDE)ity ofdata to the registry steering committee to release pooled
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With the assistance of IDE trial data managers, NERI
successfully incorporated the IDE datasets of four of the
five FDA-approved EGs into a common database.
Because each of the IDE trials was independently de-
signed to compare a single EG with its surgical control
group for purposes of FDA market approval, there was no
uniformity among the trials with regard to numbers of
patients, inclusion and exclusion criteria, or definitions of
endpoint variables. Nonetheless, the similar long-term end
points and completeness of follow-up far outweighed the
differences among the IDE trials. This allowed meaningful
data pooling reflecting the overall results of EVAR rather
than the outcomes of any specific device. The results of
individual EG-IDE trials have been published and are avail-
able in the literature3-9 along with publications that com-
pare differing devices.10-12
The Lifeline Registry data show that EVAR is a safe and
effective treatment for selected patients with infrarenal
AAA and that EVAR appears to be durable out to 6 years of
follow-up. The safety of EVAR was demonstrated by a low
operative mortality rate (1.7%), which was no different
from surgical controls (1.4%). It should be noted that this
low operative mortality rate was achieved even though EG
patients were significantly older and sicker than the SC
patients and included patients at high risk for open surgery.
Current operative mortality rates for men and women
undergoing elective open surgical repair are reported to be
5% to 6%.13-17 Although some reports suggest a higher
operative mortality rate for women undergoing open re-
pair,18,19 there was no difference in operative mortality
between women and men in the Lifeline Registry.
Effectiveness of EVAR was demonstrated by a low
likelihood of aneurysm rupture among patients treated
with EG, with only 18 early and late ruptures (0.6%).
Kaplan-Meier analysis revealed a 1.3% cumulative risk of
rupture at 5 years among 2,664 EG-IDE patients. This is
Table IIIB. Cox proportional hazard for all-cause
mortality in the endograft-Investigational Device
Exemption patients
Variable Hazard ratio
95% Hazard
ratio
confidence limits P
Age 1.042 1.029 1.055 .0001
Female 1.035 0.767 1.397 .8225
CAD/MI 1.609 1.143 2.265 .0064
CHF 2.318 1.815 2.960 .0001
Hypertension 1.006 0.827 1.223 .9548
COPD 1.836 1.511 2.232 .0001
DM 1.153 0.880 1.513 .3022
Renal failure 1.566 1.062 2.311 .0237
Aneurysm size 1.018 1.009 1.027 .0001
CAD, Coronary artery disease; MI, myocardial infarction; CHF, congestive
heart failure; COPD, chronic obstructive pulmonary disease; DM, diabetes
mellitus.lower than the 1% per year rupture rate of small aneurysms(5.5 cm) followed in prospective, randomized clinical
trials.20,21 The risk of rupture after EVAR was three times
higher in women (2.1%) than men (0.7%), which is consis-
tent with other reports of a three- to fourfold increase in
rupture risk among women.20,22,23 Although no ruptures
were reported among surgical controls in the registry,
follow-up of SC patients after 1 year was not as rigorous as
EG patients, with a requirement to report only survival
status. Prospective clinical trials of open aneurysm repair
report that the risk of rupture is not eliminated after open
repair.13-15,22
Durability of EVAR was demonstrated by a persisting
low risk of aneurysm rupture and AAA-related death. Rup-
ture rate remained stable at 1% by Kaplan-Meier analysis
over a 6-year period, with no suggestion of an increasing
risk of late rupture. Similarly, AAA-related death rate re-
mained stable at 2% by Kaplan-Meier analysis over a 6-year
period with no suggestion of an increasing risk of late
AAA-related death. These results are in contrast to EURO-
STAR Registry reports showing an increasing risk of late
rupture and AAA-related death 3 years after EVAR.24,25
These differences may be related to the high proportion of
patients in the EUROSTAR Registry treated with early
EGs that are no longer in clinical use.24,26,27
Durability was further demonstrated by a low surgical
conversion rate of 3% at 1 year and 5% at 6 years by
Kaplan-Meier analysis, with no increasing risk of late con-
versions. Late surgical conversions were well tolerated, with
no deaths among the 28 patients requiring conversion30
days after the primary procedure. By contrast, the EURO-
STAR Registry found an increasing risk of late surgical
conversion, with 9% of patients requiring conversion at 4
years.24,25 The Lifeline Registry found a higher risk of
surgical conversion in women, which was largely related to
perioperative issues of small iliac access arteries (19 of 21
conversions in women occurred 30 days). There was no
increased risk of late conversion (30 days) in women
(2/225, 0.9%) compared with men (19/1875, 1.0%). In-
terestingly, although women experienced a higher risk of
both surgical conversion and rupture, there was no differ-
ence in AAA-related death between women and men in the
Lifeline Registry.
Despite the fact that the Lifeline Registry contains
significant numbers of SC patients, evaluation of long-term
outcomes of EVAR compared with open surgery is com-
promised by the limited long-term data for SC patients.
Although the FDA required 5-year follow-up data on all
EG-IDE patients, survival status alone was required on
SC-IDE patients after 1 year. No late SC patient deaths in
the registry were reported to have been due to an aneu-
rysm-related cause and no late ruptures were recorded
among SC patients. However, ruptures have been reported
after successful elective open surgical repair in prospective
clinical trials.14,15,20 In a study of late outcome after elec-
tive open aneurysm repair, Hallett et al28 found that 2.6%
of patients died as a result of some graft-related complica-
tion at a mean follow-up time of 5.8 years. Published results
on the long-term outcome of open repair suggest that late
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mean annual rate of 0.28%.18,21,28-30
Five-year survival after EVAR was lower in Lifeline
(66%) than in the EUROSTAR Registry (75%).24 How-
ever, it should be noted that EG patients in Lifeline were 2
years older (73 years) than patients in EUROSTAR (71
years).25 Five-year survival after open repair has been re-
ported to be 64% to 77%.3,14,15,18,21 The primary predic-
tors of mortality in Lifeline were similar to other reports,
namely age, cardiac comorbidity, and preoperative chronic
obstructive pulmonary disease and renal failure. Although
women in Lifeline were 3 years older than the men, there
was no statistically significant difference in 5-year survival
between women and men.
Most patients in the Lifeline Registry are from the
Guidant AnCure and Medtronic AneuRx clinical trials,
which were the first IDE clinical trials and the first devices
to be approved by the FDA. Most of the surgical conver-
Fig 3. Kaplan-Meier (K-M) analysis of rupture of en
versus surgical controls (SC).sions in the registry are from the early EVT/AnCure IDEexperience, which includes the initial EVAR learning phase
for most investigators in the trial. The surgical conversion
rate decreased significantly in later phases of the Guidant
trial.3 Surgical conversions were not, however, limited to
the AnCure device and have occurred with all endovascular
devices in the registry. Most ruptures in the registry are
from the early AneuRx IDE experience. Published reports
from the AneuRx trial indicated that the risk of rupture was
higher in patients treated with the early “stiff” device,
which was later replaced with a flexible design.38 Ruptures
have been reported with all endovascular devices5,8,9,33,38
and occurred in three of the four IDE clinical trials in the
registry. The rupture risk with each of the devices in the
registry is very low, and the risk does not appear to increase
in late follow-up. Nonetheless, the potential for rupture
remains with all devices, and patients should continue to be
closely followed over time.
Secondary outcome measures after EVAR, such as en-
ft-Investigational Device Exemption (EG-IDE) groupdogradoleak, aneurysm enlargement, endograft migration, and
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These secondary end points have been discussed extensively
in the literature.24,31-37 Most of the secondary interven-
tional procedures (85%) in the Lifeline Registry were
performed 30 days after the endograft procedure. Al-
though secondary interventional procedures were re-
quired in 16% of EG patients after 1 year and 22% of EG
patients after 5 years, the long-term primary outcome
measures of EVAR remained stable, with no suggestion
of diminishing favorable long-term results. It should be
recognized, however, that Lifeline data extends only
Fig 4. Kaplan-Meier (K-M) analysis of surgical conv
Table IIIC. Cox proportional hazard for rupture in the
endograft-Investigational Device Exemption patients
Variable Hazard ratio
95% Hazard ratio
confidence limits P
Age 1.023 0.963 1.087 .4615
Female 3.419 1.135 10.298 .0288
CAD/MI 5791792 0.000 — .9922
CHF 0.622 0.081 4.780 .6481
Hypertension 1.318 0.459 3.786 .6079
COPD 0.873 0.278 2.741 .8165
DM 0.434 0.057 3.294 .4192
Renal failure 0.000 0.000 — .9969
Aneurysm size 1.060 1.030 1.091 .0001
CAD, Coronary artery disease; MI, myocardial infarction; CHF, congestive
heart failure; COPD, chronic obstructive pulmonary disease; DM, diabetes
mellitus.(EG-IDE) group.through 6 years, and that continuing and ongoing long
term follow up will be required of EG patients to deter-
mine the ultimate long-term outcome.
CONCLUSIONS
Endovascular aneurysm repair using FDA-approved
endografts is safe and effective in preventing aneurysm
rupture and avoiding AAA-related death in the great ma-
jority of patients undergoing treatment. EVAR is durable,
with a low long-term risk of rupture and AAA-death and a
low likelihood that surgical conversion will be needed.
Results of EVAR are favorable, even in the older higher-risk
population of patients who are poor candidates for surgery.
Women who undergo endovascular aneurysm repair are at
higher risk of aneurysm rupture and surgical conversion
than men but exhibit the same low risk of aneurysm related
death as men. Thus, EVAR is a safe, effective, and durable
treatment for anatomically suited patients with infrarenal
AAA.
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